novo nordisk septerna

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Reuters on MSN · 2d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Seeking Alpha on MSN · 2d

Novo Nordisk in pact with Septerna for oral obesity drugs

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.

PMLive2h

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Zacks.com on MSN10m

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results